

Weekly Evidence Surveillance 31/07/2026

31/07/2026	ECDC	Communicable disease threats report, 27 - 31 July 2026, week 31	31/07/2026	The ECDC Communicable Disease Threats Report (CDTR) is a weekly bulletin for epidemiologists and health professionals on active public health threats. This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 27 - 31 July 2026, and includes updates on Ebola, West Nile Virus infections, Crimean-Congo haemorrhagic fever, dengue, avian influenza A(H9N2), expert deployment, cholera, chikungunya virus disease, Vibrio, World Pride, and an overview of respiratory virus epidemiology in the EU/EEA.	RP	Emerging Infectious Diseases
31/07/2026	WHO	Routine health information system and health facility data for neglected tropical diseases: Taenia solium taeniasis and cysticercosis	31/07/2026	This guidance was developed based on a template provided to health programmes by the WHO Division of Data, Analytics and Delivery for Impact. WHO regional advisers and disease focal points in the WHO Global Neglected Tropical Diseases Programme provided technical content in alignment with the road map. A drafting team comprising WHO technical officers and Taenia solium taeniasis and cysticercosis disease experts working at global, regional and country levels contributed to the writing and review of initial drafts of the document. Independent disease experts and selected national programme managers from endemic countries reviewed the guidance for technical accuracy and relevance.	RP	Emerging Infectious Diseases
31/07/2026	WHO	Key ingested per- and poly-fluoroalkyl substances	30/07/2026	This report provides a high-level overview of the landscape review. 18 PFAS and 6 health effect categories are recommended for further	RP	Cross-Cutting / Other Public Health Topics

		(PFAS) and their health effects: landscape review		evaluation. The findings provide a foundation for subsequent, more detailed, systematic evidence reviews to support the development of health-based values for PFAS.		
31/07/2026	WHO	Towards a greener pharmaceuticals' regulatory highway: a framework for regulators as enablers of decarbonization	29/07/2026	This framework provides a roadmap for how pharmaceutical regulatory systems can support innovation that reduces the climate impact of medicines for human use while maintaining standards of safety, quality and efficacy and ensuring timely, affordable and equitable access for patients. Developed as a follow-up to the WHO Call for Action on a greener pharmaceuticals' regulatory highway (2024), it examines the contribution of pharmaceutical products to greenhouse gas emissions across their life cycle and explores how existing regulatory functions can facilitate decarbonization without expanding regulatory mandates or compromising public health objectives, access, affordability or supply security. Organized around three pillars—awareness and capacity-building; guidance, tools and standards; and innovation through regulatory pathways—the framework identifies opportunities to strengthen regulatory capabilities, promote internationally aligned methodologies and reporting approaches, expand digital transformation, scientific advice, reliance mechanisms and collaborative initiatives, and support sustainability-driven innovation. It concludes that coordinated action by regulators, WHO and other stakeholders is essential to advance lower-carbon pharmaceutical systems while building on existing regulatory frameworks and partnerships.	RP	Environment & Health
31/07/2026	WHO	WHO guidelines on leishmaniases: treatment	28/07/2026	These guidelines provide updated WHO recommendations on the pharmacological	RP	Emerging Infectious Diseases

		of visceral leishmaniasis and post-kala-azar dermal leishmaniasis in eastern Africa and South-East Asia		treatment of visceral leishmaniasis and post-kala-azar dermal leishmaniasis in eastern Africa and South-East Asia. They address treatment of visceral leishmaniasis in eastern Africa, relapse in South-East Asia, and post-kala-azar dermal leishmaniasis in both regions, incorporating new evidence from clinical trials and systematic reviews. Recommendations cover monotherapies and combination regimens involving paromomycin, miltefosine, sodium stibogluconate and liposomal amphotericin B, and apply to HIV-negative patients.		
31/07/2026	WHO	Global health sector strategies on HIV, viral hepatitis and sexually transmitted infections, 2022–2030: 2026 mid-term progress report	27/07/2026	This report is the second in a series of biennial progress reports on the implementation of the Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections (STIs) for the period 2022–2030.	RP	Sexual Health
31/07/2026	WHO	Consolidated guidance for strengthening national routine surveillance systems: updated HIV case definitions, advanced HIV disease indicators and surveillance checklist	27/07/2026	WHO's new consolidated guidance define the core components of a strong routine HIV surveillance system. Bringing together updated HIV and advanced HIV disease case definitions, a minimum dataset for HIV case surveillance, priority indicators for monitoring advanced HIV disease and a practical surveillance checklist, the guidance provides countries with a framework for improving the quality, consistency and reliability of routine HIV data. Together these components support the monitoring of HIV diagnoses, treatment outcomes and mortality, while strengthening the use of routine data for public health action.	RP	Public Health Systems & Tools/Policies/Reviews
31/07/2026	UKHSA	The national gonorrhoea vaccination programme using 4CMenB vaccine: frequently asked questions	31/07/2026	Answers to frequently raised questions relating to the national gonorrhoea vaccination programme using 4CMenB vaccine.	RP	Vaccination Preventable Disease Guidance

31/07/2026	UKHSA	Ebola and Marburg haemorrhagic fevers: outbreaks and case locations	30/07/2026	Information about incidents and outbreaks of Ebola and Marburg, both viral haemorrhagic fevers (VHF).	RP	Emerging Infectious Diseases
31/07/2026	UKHSA	Health Protection Report volume 20 (2026)	30/07/2026	A national public health bulletin from the UK Health Security Agency (UKHSA).	RP	Public Health Systems & Tools/Policies/Reviews
31/07/2026	UKHSA	National partnership agreement on asylum seeker health in England	30/07/2026	A national partnership agreement on meeting the health and wellbeing needs for people seeking asylum in England from 2025 to 2028.	RP	Cross-Cutting / Other Public Health Topics
31/07/2026	UKHSA	National measles guidelines	30/07/2026	How to manage cases of suspected measles: what patient details to take, who to notify and assessing risk of disease spreading in close contacts.	RP	Emerging Infectious Diseases
31/07/2026	UKHSA	MERS-CoV: self-isolating awaiting MERS-CoV test result	30/07/2026	This is an information sheet for individuals self-isolating whilst awaiting a MERS-CoV test result.	RP	Emerging Infectious Diseases
31/07/2026	UKHSA	Sharp rise in cyclospora infections linked to Mexico travel	30/07/2026	Travellers urged to follow food and water hygiene advice to reduce risk of infection	RP	Cross-Cutting / Other Public Health Topics
31/07/2026	UKHSA	Respiratory syncytial virus (RSV): vaccination for older adults	30/07/2026	Information on respiratory syncytial virus (RSV) and the benefits of vaccination for adults and resources to promote the vaccination to older adults.	RP	Vaccination Preventable Disease Guidance
31/07/2026	UKHSA	Respiratory syncytial virus (RSV) vaccination programme	30/07/2026	Publications relating to the new respiratory syncytial virus (RSV) vaccination programme.	RP	Vaccination Preventable Disease Guidance
31/07/2026	UKHSA	UKHSA ad hoc statistical publications	30/07/2026	UK Health Security Agency additional statistical analyses not included in our standard official statistics releases.	RP	Cross-Cutting / Other Public Health Topics
31/07/2026	UKHSA	Haemophilus influenzae: lab reports by age group and serotype	30/07/2026	Laboratory reports on cases of Haemophilus influenzae in England.	RP	Cross-Cutting / Other Public Health Topics
31/07/2026	UKHSA	Tuberculosis (TB): diagnosis, screening, management and data	30/07/2026	Information on the diagnosis, screening, epidemiology and public health strategy for tuberculosis and other mycobacterial diseases.	RP	Emerging Infectious Diseases

31/07/2026	UKHSA	Mycoplasma genitalium antimicrobial resistance surveillance (MARS)	30/07/2026	Data on the latest findings relating to antimicrobial resistance in Mycoplasma genitalium from specimens collected in sexual health clinics across England.	RP	Antimicrobial Resistance (AMR)
31/07/2026	UKHSA	Pertussis immunisation in pregnancy: vaccine coverage (England)	30/07/2026	Vaccine uptake data and commentary about the pertussis (whooping cough) vaccination programme for pregnant women.	RP	Vaccination Preventable Disease Guidance
31/07/2026	UKHSA	Botulism: clinical and public health management	28/07/2026	Information for healthcare professionals on the diagnosis and treatment of infant botulism, foodborne botulism and wound botulism.	RP	Emerging Infectious Diseases
31/07/2026	PHA-NI	Feeling anxious? A guide to things that can help leaflet	28/07/2026	This leaflet gives some ideas for ways to help manage anxiety and feel more able to cope, along with where to find support if you need it.	RP	Cross-Cutting / Other Public Health Topics
31/07/2026	PHA-NI	Help protect yourself from meningitis and septicaemia - your guide to the free MenB vaccine	28/07/2026	This leaflet describes the MenB vaccine available to eligible young people this autumn 2026.	RP	Vaccination Preventable Disease Guidance
31/07/2026	PH Ontario	Viral Hemorrhagic Fevers	27/07/2026	Viral hemorrhagic fevers (VHFs) are a group of viral illnesses caused by different virus families. Common symptoms include fever, headache, muscle and joint pain, fatigue, abdominal pain, vomiting, and diarrhea. Illness severity can range from mild to severe, depending on the virus and the individual. In some people, VHF-causing viruses can damage blood vessels and affect blood clotting, leading to bruising or bleeding. Severe disease may involve internal bleeding, organ failure, and death. Examples of VHFs include Ebola disease, Marburg disease, and Lassa fever.	RP	Emerging Infectious Diseases
31/07/2026	PH Ontario	Ontario Vector-Borne Disease Tool	29/07/2026	The Ontario Vector-borne Disease Tool offers comprehensive surveillance data on vector-borne diseases (VBDs) in Ontario. This interactive resource allows users to explore trends in human cases for anaplasmosis, babesiosis, Lyme disease, Powassan virus infection, and West Nile	RP	Public Health Systems & Tools/Policies/Reviews

				virus illness, as well as surveillance data for mosquitoes and ticks, and blacklegged tick established risk areas. VBD data are available across multiple dimensions, including year-to-date and weekly case counts, mosquito and tick species distribution, and positive surveillance results.		
31/07/2026	HPRA	Guide to Controlled Drugs Documentation, Storage and Security Requirements for Operators	31/07/2026	This document provides guidance to operators of controlled drugs located in Ireland regarding the requirements for documentation, storage and security that are set out in the Misuse of Drugs Act 1977 (as amended) (the 'Act'), and the various Orders and Regulations made thereunder, of which the Principal Regulations are the Misuse of Drugs Regulations 2017 (as amended) (the 'Regulations'). Additional requirements pertaining to the Medical Cannabis Access Programme are not outlined in this document and can be found on the Department of Health's website.	RP	Public Health Systems & Tools/Policies/Reviews
31/07/2026	HIQA	National Guidance for the Responsible and Safe Use of Artificial Intelligence in Health and Social Care Services	29/07/2026	This national guidance is intended for use by all health and social care services in Ireland. Its purpose is to support services and staff by promoting awareness and good practice about the responsible and safe use of Artificial Intelligence (AI) in health and social care settings, while educating people who use services on what to expect when AI is used in their care.	RP	Public Health Systems & Tools/Policies/Reviews
31/07/2026	PHS	Scottish Public Health Observatory quarterly update	28/07/2026	This release by Public Health Scotland (PHS) provides the Scottish Public Health Observatory (ScotPHO) quarterly update on a number of topic areas. Of these topics, Diabetes pages contain new data.	RP	Public Health Systems & Tools/Policies/Reviews
31/07/2026	PHS	Protect yourself against respiratory syncytial virus (RSV)	27/07/2026	This guide provides information on the respiratory syncytial virus (RSV) vaccine which is offered to older adults to help protect them against infections caused by RSV.	RP	Emerging Infectious Diseases

31/07/2026	IDSA	Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial	29/07/2026	VH-499 monotherapy demonstrated highly potent antiviral activity, was well tolerated, and had a favorable safety profile. These results support further development of VH-499 as part of a complete long-acting regimen for HIV-1 treatment (ClinicalTrials.gov, NCT06039579).	RP	Sexual Health
31/07/2026	IDSA	Right Antibiotic, Right Discharge: Ethical Tensions Between Antimicrobial Stewardship and Social Vulnerability	28/07/2026	In a case of a patient with postoperative septic arthritis and hardware-associated osteomyelitis due to methicillin-susceptible Staphylococcus aureus that is susceptible to multiple oral agents, the clinician must navigate not only a treatment decision between oral and intravenous antibiotics but also the ethical tension between evidence-based practice and the patient's social instability. We examined 3 interrelated ethical conflicts: balancing clinician–patient relationship with organizational priorities, weighing the benefits and harms of competing treatment decisions, and considering how patient vulnerability may shape professional duties.	RP	Antimicrobial Resistance (AMR)
31/07/2026	IDSA	Evaluating the Effectiveness of Antivirals for COVID-19 in the Post-vaccine, Omicron Era: A Systematic Review and Meta-analysis	30/07/2026	In vaccinated populations, RCTs have not demonstrated a reduction in hospitalization or death among populations treated with nirmatrelvir-ritonavir or with molnupiravir. However, RCTs of nirmatrelvir-ritonavir had limited statistical power to detect clinically important differences. Observational studies of nirmatrelvir-ritonavir, but not molnupiravir, consistently suggested a benefit against these outcomes.	RP	Emerging Infectious Diseases
31/07/2026	Evidence Alerts	Respiratory Outbreak Mitigation With Point-of-Care Testing in Long-Term CareA Randomized Clinical Trial	06/07/2026	The trial results suggest that seasonal adoption of POC-RMPCR in NHs would avoid an estimated 4 hospital transfers per 100 beds, equivalent to 64 000 across the US each respiratory season.	RP	Public Health Systems & Tools/Policies/Reviews
31/07/2026	WOAH	Rabies detected in Cape fur seals highlights an	17/07/2026	The detection of sustained rabies transmission in Cape fur seals in southern Africa marks an	RP	Cross-Cutting / Other Public Health Topics

		unprecedented shift in rabies ecology		unprecedented development in the ecology of rabies and raises important questions for wildlife conservation, animal public health and transboundary disease preparedness.		
--	--	---	--	---	--	--